BeiGene

BeiGene’s Tislelizumab Improves Survival in Esophageal Cancer Study
BeiGene’s Tislelizumab Improves Survival in Esophageal Cancer Study
BioSpace
BeiGene
monoclonal antibodies
tislelizumab
clinical trials
esophageal cancer
Flag link:
BeiGene, Novartis in pact to develop tislelizumab for cancer settings
BeiGene, Novartis in pact to develop tislelizumab for cancer settings
Seeking Alpha
Novartis
BeiGene
tiselizumab
cancer
drug development
Flag link:
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice
Fierce Pharma
AstraZeneca
BeiGene
JNJ
AbbVie
Calquence
Brukinsa
Imbruvica
CLL
ASH2020
Flag link:
$200M investment to advance clinical programs for Ambrx
$200M investment to advance clinical programs for Ambrx
MedCity News
Ambrx
oncology
Astellas
BeiGene
Bristol-Myers Squibb
Flag link:
BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
BeiGene beefs up PD-1 data with positive PhIII results for tislelizumab, this time in metastatic NSCLC
Endpoints
BeiGene
metastatic non-small cell lung cancer
Flag link:
Esmo 2020 – some backing for Beigene’s unusual combo approach
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
ESMO
BeiGene
urothelial cancer
Flag link:
BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies
BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies
Pharmaceutical Business Review
BeiGene
SInglomics
COVID-19
Flag link:
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
BeiGene expands pipeline and hops on board a quest to cure hep B, inking a $540M deal with a fellow upstart biotech
Endpoints
China
BeiGene
Assembly Biosciences
hepatitis B
Flag link:
Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale
Chinese Biotech Beigene to Raise $2.1 Billion in Share Sale
Bloomberg
China
BeiGene
Amgen
NASDAQ
Flag link:
Important catalysts approach for smaller biotechs
Important catalysts approach for smaller biotechs
EP Vantage
BeiGene
Turning Point Therapeutics
Intra-Cellular Therapies
Immunovant
Caplyta
Brukinsa
repotrectinib
IMVT-1401
clinical trials
Flag link:
BeiGene reports positive Phase III interim analysis for lung cancer drug
BeiGene reports positive Phase III interim analysis for lung cancer drug
MedCity News
BeiGene
clinical trials
immunotherapy
lung cancer
tislelizumab
non-squamous non-small cell lung cancer
Flag link:
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BeiGene’s Tislelizumab Could Challenge Merck’s Keytruda in the Checkpoint Inhibitor Market
BioSpace
BeiGene
tiselizumab
non-small cell lung cancer
Merck
Keytruda
Flag link:
Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Amgen wades deeper into Asia with full control of an Astellas Japanese JV
Fierce Pharma
Amgen
Astellas
Japan
BeiGene
China
Flag link:
BeiGene lung cancer treatment meets main goal in late-stage study
BeiGene lung cancer treatment meets main goal in late-stage study
Reuters
BeiGene
cancer
lung cancer
clinical trials
tislelizumab
Flag link:
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Amgen to Sell Cancer Drugs in China Thanks to $2.7B Deal with BeiGene
Xtalks
Amgen
BeiGene
oncology
China
Flag link:
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese market
Pharmaforum
Boehringer Ingelheim
China
BeiGene
drug manufacturing
Flag link:
3 Blockbuster Cancer Drug Launches to Watch in 2020
3 Blockbuster Cancer Drug Launches to Watch in 2020
Motley Fool
FDA
drug approvals
cancer
drug launches
AstraZeneca
Enhertu
Padcev
Seattle Genetics
BeiGene
Brukinsa
Flag link:
Corporate and regulatory developments over the Christmas period
Corporate and regulatory developments over the Christmas period
EP Vantage
Astellas
M&A
Qiagen
AstraZeneca
Bausch Health
BeiGene
Celyad
Immunomedics
Merck
Merck KGaA
Ono Pharmaceutical
Pfizer
Pharming
Xyphos Biosciences
Flag link:
5 New Drug Approvals the FDA Gave Top Priority
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
Flag link:
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Flag link:

Pages